Actively Recruiting
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Led by Astellas Pharma Global Development, Inc. · Updated on 2026-04-29
500
Participants Needed
224
Research Sites
175 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Zolbetuximab is being studied in people with cancer in and around the stomach or where the food pipe (esophagus) joins the stomach, called gastroesophageal junction (GEJ) cancer. Zolbetuximab with chemotherapy may be used to treat stomach and GEJ cancer when the cancer cells do not have a protein called HER2 (human epidermal growth factor receptor 2) on their surface (HER2-negative) but do have a protein called Claudin 18.2 (Claudin 18.2-positive). Zolbetuximab is thought to work by attaching to the Claudin 18.2 protein in their tumor, which switches on the body's immune system to attack the tumor. Certain stomach and GEJ cancers may be treated with immunotherapy, which helps the body's immune system fight cancer. This study will give more information about how well zolbetuximab works when given with an immunotherapy medicine called pembrolizumab and chemotherapy. In this study, adults with stomach cancer or GEJ cancer will either be given zolbetuximab with pembrolizumab and chemotherapy or a placebo with pembrolizumab and chemotherapy. A placebo looks like zolbetuximab but doesn't have any medicine in it. The main aim of the study is to check how long people with stomach cancer and GEJ cancer live after treatment with zolbetuximab with pembrolizumab and chemotherapy compared to placebo with pembrolizumab and chemotherapy. Adults with locally advanced unresectable or metastatic stomach cancer or GEJ cancer can take part. Locally advanced means the cancer has spread to nearby tissue. Unresectable means the cancer cannot be removed by surgery. Metastatic means the cancer has spread to other parts of the body. A tumor sample (biopsy) of their cancer will have the Claudin 18.2 protein, PD-L1 protein, and be HER2-negative. They may have been previously treated with certain standard therapies. People cannot take part if they need to take medicines to suppress their immune system, have blockages or bleeding in their gut, have specific uncontrollable cancers such as symptomatic or untreated cancers in the nervous system, or have a specific heart condition, or infections. The study treatments are either zolbetuximab with pembrolizumab and chemotherapy, or placebo with pembrolizumab and chemotherapy. People who take part will receive just 1 of the study treatments by chance. The people in the study and the study doctors will not know who takes which of the study treatments. Study treatment will be given in 6-week (42-day) cycles. The study treatment is mainly given to people slowly through a tube into a vein. This is called an infusion. People will receive study treatment as follows: Zolbetuximab or placebo: 1 infusion every 2 or 3 weeks (2 or 3 infusions in a cycle) together with: Chemotherapy (1 of the following types of chemotherapy): 1. CAPOX (capecitabine and oxaliplatin): 1 infusion of oxaliplatin every 3 weeks (2 infusions in a cycle). People will also take 1 tablet of capecitabine twice a day for 2 weeks (14 days) at the start of each cycle (Day 1) and again in the middle of each cycle (Day 22). After 8 study treatments people will receive capecitabine only. 2. Modified FOLFOX6 or mFOLFOX6 (5-fluorouracil, folinic acid and oxaliplatin): 1 infusion every 2 weeks (3 infusions in a cycle). After 12 study treatments people will receive folinic acid and fluorouracil only, instead of mFOLFOX6. Pembrolizumab: 1 infusion every 3 or 6 weeks (1 or 2 infusions in a cycle). People can be in the study and will receive study treatment until their cancer worsens, they cannot tolerate the study treatment, or they need to start another cancer treatment. People may receive pembrolizumab for up to 2 years. People will visit the clinic on certain days to receive their study treatment and have health checks. The study doctors will check if people had any medical problems from taking zolbetuximab or the other study treatments. On some visits they will have scans to check for any changes in their cancer. People will have the option of giving a tumor sample if they stop treatment because their cancer has worsened. People will visit the clinic after they stop their study treatment. People will be asked about any medical problems and will have a health check. People will continue to have scans every 9 or 12 weeks to check for any changes in their cancer. They will have telephone health checks every 3 months. The number of visits and checks done at each visit will depend on the health of each person and whether they completed their study treatment or not.
CONDITIONS
Official Title
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma
- Radiographically confirmed locally advanced, unresectable or metastatic disease within 28 days before randomization
- Radiologically evaluable disease according to RECIST V1.1 criteria within 28 days before randomization
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
- Predicted life expectancy of at least 12 weeks
- Eligible to receive mFOLFOX6 or CAPOX chemotherapy and pembrolizumab
- Female participants must not be pregnant and meet contraception or breastfeeding restrictions
- Male participants must agree to use contraception or abstinence during and after treatment
- Tumor must be HER2-negative
- Tumor must express Claudin 18.2 in at least 75% of tumor cells with moderate to strong staining
- Tumor must have PD-L1 combined positive score (CPS) of 1 or higher
- Participants with microsatellite instability-high or mismatch repair deficiency may enroll if PD-L1 positive
- Meet laboratory test criteria within 14 days prior to randomization
- Agree not to participate in another interventional study during this study
You will not qualify if you...
- Prior severe allergic reaction or intolerance to zolbetuximab, pembrolizumab, mFOLFOX6, or CAPOX
- Complete or partial gastric outlet syndrome with persistent vomiting
- Significant gastric bleeding or untreated gastric ulcers
- Unresolved or history of non-infectious pneumonitis
- History of central nervous system metastases or carcinomatous meningitis from gastric/GEJ cancer
- Positive test or active infection with HIV, hepatitis B or C under certain conditions
- Active infection requiring systemic therapy unresolved within 7 days prior to randomization
- Active autoimmune disease requiring systemic treatment within past 3 months
- Clinically significant disease or comorbidity affecting safe treatment delivery
- Another malignancy requiring treatment
- Known dihydropyrimidine dehydrogenase (DPD) deficiency
- Peripheral neuropathy greater than grade 1
- Sinusoidal obstruction syndrome if not stable or improving
- Significant cardiovascular disease including heart failure, recent myocardial infarction, or arrhythmias
- Ongoing or previous interstitial lung disease, active diverticulitis or peptic ulcer disease, or organ transplant
- Prior systemic chemotherapy or immunotherapy for advanced gastric/GEJ cancer beyond allowed limits
- Recent systemic immunosuppressive therapy except physiologic replacement doses
- Recent major surgery or radiotherapy without recovery
- Prior treatment with CLDN18.2 agents
- Recent live or live-attenuated vaccine
- Concurrent or recent investigational agents or devices
- Conditions making participation unsuitable or unsafe
- Pernicious anemia or vitamin B12 deficiency anemias
- History or active tuberculosis infection
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 224 locations
1
UAB Medicine - UAB Hospital
Birmingham, Alabama, United States, 35294
Actively Recruiting
2
TOI Clinical Research
Cerritos, California, United States, 90703
Actively Recruiting
3
The Angeles Clinic and Research Institute, West Los Angeles Office
Los Angeles, California, United States, 90025
Actively Recruiting
4
Hartford HealthCare - Hartford Hospital
Hartford, Connecticut, United States, 06102
Actively Recruiting
5
Yale University School of Medicine
New Haven, Connecticut, United States, 06510
Actively Recruiting
6
Piedmont Physician Medical Oncology Atlanta
Atlanta, Georgia, United States, 30318
Actively Recruiting
7
Northwestern Memorial Hospital
Chicago, Illinois, United States, 60611
Actively Recruiting
8
Franciscan Health Oncology and Hematology Specialists
Indianapolis, Indiana, United States, 46237
Actively Recruiting
9
Holden Comprehensive Cancer Center
Iowa City, Iowa, United States, 52242
Actively Recruiting
10
University of Kansas Cancer Center
Westwood, Kansas, United States, 66205
Actively Recruiting
11
Saint Elizabeth Medical Center Edgewood
Edgewood, Kentucky, United States, 41017
Actively Recruiting
12
University of Maryland Medical System - University of Maryland Medical Center
Baltimore, Maryland, United States, 21021
Actively Recruiting
13
Dana Farber/Harvard Cancer Center
Boston, Massachusetts, United States, 02215
Actively Recruiting
14
University of Michigan Health System
Ann Arbor, Michigan, United States, 48109
Actively Recruiting
15
Barbara Ann Karmanos Cancer Center
Detroit, Michigan, United States, 48201
Actively Recruiting
16
Henry Ford Cancer Institute-Henry Ford Hospital
Detroit, Michigan, United States, 48201
Actively Recruiting
17
Metro Minnesota Community Oncology Research Consortium (MMCORC)
Saint Louis Park, Minnesota, United States, 55426
Actively Recruiting
18
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68105
Actively Recruiting
19
Oncology Hematology West PC dba Nebraska Cancer Specialists
Omaha, Nebraska, United States, 68130
Actively Recruiting
20
NYU Langone Medical Center
New York, New York, United States, 10016
Actively Recruiting
21
Montefiore Medical Center
The Bronx, New York, United States, 10461
Actively Recruiting
22
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States, 27599
Actively Recruiting
23
Duke University Medical Center - Duke Cancer Centre
Durham, North Carolina, United States, 27710
Actively Recruiting
24
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
Actively Recruiting
25
The University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920
Actively Recruiting
26
Vanderbilt University Medical Center
Nashville, Tennessee, United States, 37232
Actively Recruiting
27
Texas Oncology-Baylor Charles A Sammons Cancer Center
Dallas, Texas, United States, 75246
Actively Recruiting
28
The Center For Cancer And Blood Disorders (Texas Cancer Care)
Fort Worth, Texas, United States, 76104
Actively Recruiting
29
Houston Methodist Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
30
Utah Cancer Specialists Cancer Center - Medical Oncology
Salt Lake City, Utah, United States, 84106
Actively Recruiting
31
AU61002
Kogarah, New South Wales, Australia
Actively Recruiting
32
AU61004
Brisbane, Queensland, Australia
Actively Recruiting
33
AU61003
Clayton, Victoria, Australia
Actively Recruiting
34
AU61001
Fitzroy, Australia
Actively Recruiting
35
BE32002
Bonheiden, Belgium
Actively Recruiting
36
BE32001
Brussels, Belgium
Actively Recruiting
37
BE32006
Edegem, Belgium
Actively Recruiting
38
BE32003
Ghent, Belgium
Actively Recruiting
39
Site BE32005
Leuven, Belgium
Actively Recruiting
40
BE32004
Liège, Belgium
Actively Recruiting
41
Site BR55014
Belo Horizonte, Brazil
Actively Recruiting
42
Site BR55008
Jaú, Brazil
Actively Recruiting
43
Site BR55004
Lages, Brazil
Actively Recruiting
44
Site BR55003
Porto Alegre, Brazil
Actively Recruiting
45
Site BR55006
São Caetano do Sul, Brazil
Actively Recruiting
46
Site BR55001
São José do Rio Preto, Brazil
Actively Recruiting
47
Anhui Provincial Cancer Hospital
Hefei, Anhui, China, 230031
Actively Recruiting
48
Fujian Provincial Hospital - Department of Medical Oncology
Fuzhou, Fujian, China
Actively Recruiting
49
Sun Yat-sen University - Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
50
Sun Yat-sen University - Cancer Center
Guangzhou, Guangdong, China, 510555
Actively Recruiting
51
Harbin Medical University Cancer Hospital - Oncology
Harbin, Heilongjiang, China
Actively Recruiting
52
Henan Cancer Hospital - Oncology
Zhenngzhou, Henan, China
Actively Recruiting
53
Hubei Cancer Hospital - Oncology
Wuhan, Hubei, China, 430079
Actively Recruiting
54
Qinghai University Affiliated Hospital
Xining, Qinghai, China
Actively Recruiting
55
Renji Hospital Shanghai Jiaotong Univ School of Medicine
Shanghai, Shanghai Municipality, China, 200127
Actively Recruiting
56
Ruijin Hospital of Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, China
Actively Recruiting
57
Sichuan Cancer Hospital
Chengdu, Sichuan, China, 610200
Actively Recruiting
58
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Actively Recruiting
59
The First Affiliated Hospital of Zhejiang University
Hangzhou, Zhejiang, China
Actively Recruiting
60
Affiliated Hospital of Hebei University
Baoding, China, 71000
Actively Recruiting
61
Peking Union Medical College Hospital - Dongdan Campus
Beijing, China
Actively Recruiting
62
CZ42006
Brno, Czechia
Actively Recruiting
63
CZ42003
Prague, Czechia
Actively Recruiting
64
CZ42004
Prague, Czechia
Actively Recruiting
65
FR33016
Bordeaux, France
Actively Recruiting
66
FR-33008
Brest, France
Actively Recruiting
67
FR33012
Caen, France
Actively Recruiting
68
FR33009
Carassonne, France
Actively Recruiting
69
FR33005
Dijon, France
Actively Recruiting
70
FR33002
Lille, France
Actively Recruiting
71
FR33007
Lille, France
Actively Recruiting
72
FR33014
Lyon, France
Actively Recruiting
73
FR33017
Lyon, France
Actively Recruiting
74
FR33020
Montpellier, France
Actively Recruiting
75
FR33018
Nice, France
Actively Recruiting
76
FR33003
Paris, France
Actively Recruiting
77
FR33010
Paris, France
Actively Recruiting
78
FR33013
Paris, France
Actively Recruiting
79
FR33015
Plérin, France
Actively Recruiting
80
FR33004
Poitiers, France
Actively Recruiting
81
FR33006
Rouen, France
Actively Recruiting
82
FR33019
Saint Herbian Cedex, France
Actively Recruiting
83
FR33011
Strasbourg, France
Actively Recruiting
84
DE49013
Berlin, Germany
Actively Recruiting
85
Site DE49010
Essen, Germany
Actively Recruiting
86
DE49007
Hanover, Germany
Actively Recruiting
87
Site DE49004
Leipzig, Germany
Actively Recruiting
88
DE49001
Mainz, Germany
Actively Recruiting
89
DE49002
Saarbrücken, Germany
Actively Recruiting
90
DE49011
Schweinfurt, Germany
Actively Recruiting
91
DE49016
Wolfsburg, Germany
Actively Recruiting
92
IT39019
Bergamo, Italy
Actively Recruiting
93
IT39017
Bologna, Italy
Actively Recruiting
94
IT39009
Brescia, Italy
Actively Recruiting
95
IT39014
Candiolo, Italy
Actively Recruiting
96
IT39006
Cermona, Italy
Actively Recruiting
97
IT39011
Florence, Italy
Actively Recruiting
98
IT39007
Meldola, Italy
Actively Recruiting
99
IT-39020
Milan, Italy
Actively Recruiting
100
IT39012
Milan, Italy
Actively Recruiting
101
IT39018
Milan, Italy
Actively Recruiting
102
IT39021
Naples, Italy
Actively Recruiting
103
IT-39015
Pisa, Italy
Actively Recruiting
104
IT39004
Reggio Emilia, Italy
Actively Recruiting
105
IT39016
Roma, Italy
Actively Recruiting
106
IT39001
Rome, Italy
Actively Recruiting
107
IT39003
Torrette Di Ancona, Italy
Actively Recruiting
108
IT39022
Udine, Italy
Actively Recruiting
109
IT39002
Verona, Italy
Actively Recruiting
110
Chiba Cancer Center
Chiba, Chiba, Japan
Actively Recruiting
111
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Actively Recruiting
112
National Hospital Organization Shikoku Cancer Center
Matsuyama, Ehime, Japan
Actively Recruiting
113
Kyushu University Hospital (Hematology, Oncology & Cardiovascular medicine)
Fukuoka, Fukuoka, Japan
Actively Recruiting
114
Kyushu University Hospital(Gastrointestinal Surgery)
Fukuoka, Fukuoka, Japan
Actively Recruiting
115
National Hospital Organization Kyushu Cancer Center
Fukuoka, Fukuoka, Japan
Actively Recruiting
116
Gunma University Hospital
Maebashi, Gunma, Japan
Actively Recruiting
117
Hokkaido University Hospital
Sapporo, Hokkaido, Japan
Actively Recruiting
118
Hyogo Cancer Center
Akashi-shi, Hyōgo, Japan
Actively Recruiting
119
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Actively Recruiting
120
Kagawa University Hospital
Kida-gun, Kagawa-ken, Japan
Actively Recruiting
121
St. Marianna University Hospital
Kawasaki-shi, Kanagawa, Japan
Actively Recruiting
122
Kanagawa Cancer Ctr Hospital
Yokohama, Kanagawa, Japan
Actively Recruiting
123
Tohoku University Hospital
Sendai, Miyagi, Japan
Actively Recruiting
124
Osaka General Medical Center
Osaka, Osaka, Japan
Actively Recruiting
125
Osaka International Cancer Institute
Osaka, Osaka, Japan
Actively Recruiting
126
Osaka University Hospital
Suita-shi, Osaka, Japan
Actively Recruiting
127
Saitama Medical University International Medical Center
Hidaka-shi, Saitama, Japan
Actively Recruiting
128
Saitama Cancer Center
Kitaadachi-gun Ina-machi, Saitama, Japan
Actively Recruiting
129
Shizuoka Cancer Center
Sunto-gun, Shizuoka, Japan
Actively Recruiting
130
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Actively Recruiting
131
The Cancer Institute Hospital of JFCR
Koto-ku, Tokyo, Japan
Actively Recruiting
132
LT37001
Kaunas, Lithuania
Actively Recruiting
133
LT37002
Vilnius, Lithuania
Actively Recruiting
134
Site MX52003
Mexico City, Mexico
Actively Recruiting
135
Site MX52001
Oaxaca City, Mexico
Actively Recruiting
136
NL-31002
Leeuwarden, Netherlands
Actively Recruiting
137
NL31001
Nijmegen, Netherlands
Actively Recruiting
138
PL48005
Lubin, Lubusz Voivodeship, Poland
Actively Recruiting
139
PL48004
Warsaw, Masovian Voivodeship, Poland
Actively Recruiting
140
PL48001
Brzozów, Woj Podkarpackie, Poland
Actively Recruiting
141
PL48008
Olsztyn, Poland
Actively Recruiting
142
PL48002
Przemyśl, Poland
Actively Recruiting
143
PL48009
Swidnica, Poland
Actively Recruiting
144
PL48007
Warsaw, Poland
Actively Recruiting
145
PT35106
Almada, Portugal
Actively Recruiting
146
PT35103
Braga, Portugal
Actively Recruiting
147
PT35104
Guimarães, Portugal
Actively Recruiting
148
Site PT35102
Lisbon, Portugal
Actively Recruiting
149
Site PT35107
Lisbon, Portugal
Actively Recruiting
150
PT35105
Porto, Portugal
Actively Recruiting
151
PT35108
Porto, Portugal
Actively Recruiting
152
PT35109
Porto, Portugal
Actively Recruiting
153
RO40008
Bucharest, Romania
Actively Recruiting
154
RO40001
Cluj-Napoca, Romania
Actively Recruiting
155
RO40005
Cluj-Napoca, Romania
Actively Recruiting
156
RO40006
Cluj-Napoca, Romania
Actively Recruiting
157
RO40003
Craiova, Romania
Actively Recruiting
158
RO40002
Floreşti, Romania
Actively Recruiting
159
RO40007
Iași, Romania
Actively Recruiting
160
RO40004
Timișoara, Romania
Actively Recruiting
161
KR82011
Goyang-si, Gyeonggi-do, South Korea
Actively Recruiting
162
KR82007
Seongnam-si, Gyeonggi-do, South Korea
Actively Recruiting
163
KR82013
Suwon, Gyeonggi-do, South Korea
Actively Recruiting
164
KR82015
Suwon, Gyeonggi-do, South Korea
Actively Recruiting
165
KR82014
Hwasungun, Joellanamdo, South Korea
Actively Recruiting
166
KR82009
Cheongju-si, North Chungcheong, South Korea
Actively Recruiting
167
KR82003
Seocho-gu, Seoul, South Korea
Actively Recruiting
168
KR82004
Daegu, South Korea
Actively Recruiting
169
KR82005
Incheon, South Korea
Actively Recruiting
170
KR82001
Seoul, South Korea
Actively Recruiting
171
KR82002
Seoul, South Korea
Actively Recruiting
172
KR82006
Seoul, South Korea
Actively Recruiting
173
KR82008
Seoul, South Korea
Actively Recruiting
174
KR82010
Seoul, South Korea
Actively Recruiting
175
KR82012
Seoul, South Korea
Actively Recruiting
176
ES34022
Elche, Alicante, Spain
Actively Recruiting
177
ES34023
San Cugat Del Valles Barcelona, Cataluyna, Spain
Actively Recruiting
178
ES34019
Madrid, Madrid, Spain
Actively Recruiting
179
ES34027
Madrid, Madrid, Spain
Actively Recruiting
180
ES34002
Navarra, Pamplona, Spain
Actively Recruiting
181
ES34005
A Coruña, Spain
Actively Recruiting
182
ES34006
Barcelona, Spain
Actively Recruiting
183
ES34009
Barcelona, Spain
Actively Recruiting
184
ES34010
Barcelona, Spain
Actively Recruiting
185
ES34011
Barcelona, Spain
Actively Recruiting
186
ES34024
Barcelona, Spain
Actively Recruiting
187
ES34026
Barcelona, Spain
Actively Recruiting
188
ES34021
El Palmar, Spain
Actively Recruiting
189
ES34014
Lleida, Spain
Actively Recruiting
190
ES34003
Madrid, Spain
Actively Recruiting
191
ES34008
Madrid, Spain
Actively Recruiting
192
ES34016
Madrid, Spain
Actively Recruiting
193
ES34017
Madrid, Spain
Actively Recruiting
194
Site ES34031
Madrid, Spain
Actively Recruiting
195
ES34030
Murcia, Spain
Actively Recruiting
196
ES34013
Pozuelo de Alarcón, Spain
Actively Recruiting
197
ES34029
Santiago de Compostela, Spain
Actively Recruiting
198
ES34012
Seville, Spain
Actively Recruiting
199
ES34025
Seville, Spain
Actively Recruiting
200
ES34004
Valencia, Spain
Actively Recruiting
201
ES34007
Valencia, Spain
Actively Recruiting
202
ES34015
Zaragoza, Spain
Actively Recruiting
203
Site ES34018
Zaragoza, Spain
Actively Recruiting
204
TW-88603
Dawan, Taiwan, Taiwan
Actively Recruiting
205
TW88604
Kaohsiung City, Taiwan
Actively Recruiting
206
TW88601
Taichung, Taiwan
Actively Recruiting
207
TW88606
Tainan, Taiwan
Actively Recruiting
208
TW88605
Taipei, Taiwan
Actively Recruiting
209
Site TR90006
Ankara, Turkey (Türkiye)
Actively Recruiting
210
TR90004
Ankara, Turkey (Türkiye)
Actively Recruiting
211
Site TR90013
Konya, Turkey (Türkiye)
Actively Recruiting
212
Site TR90015
Van, Turkey (Türkiye)
Actively Recruiting
213
GB44010
Cottingham, East Riding Of Yorkshire, United Kingdom
Actively Recruiting
214
UK44001
Bristol, United Kingdom
Actively Recruiting
215
Site GB44003
Cardiff, United Kingdom
Actively Recruiting
216
GB44002
Coventry, United Kingdom
Actively Recruiting
217
UK44006
Dundee, United Kingdom
Actively Recruiting
218
GB44004
Glasgow, United Kingdom
Actively Recruiting
219
GB-44005
London, United Kingdom
Actively Recruiting
220
UK44011
London, United Kingdom
Actively Recruiting
221
UK44014
London, United Kingdom
Actively Recruiting
222
UK44015
London, United Kingdom
Actively Recruiting
223
UK44016
London, United Kingdom
Actively Recruiting
224
UK44009
Manchester, United Kingdom
Actively Recruiting
Research Team
A
Astellas Pharma Global Development Inc.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here